A review of gliptins for 2014

Alogliptin

(2014) Courtney I. Jarvis et al.   ANNALS OF PHARMACOTHERAPY

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

(2014) Kazufumi Nakamura et al.   Cardiovascular Diabetology

Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants

(2014) Shiying Wu et al.   Cardiovascular Therapeutics

Cardiovascular Actions of Incretin-Based Therapies

(2014) John R. Ussher et al.   CIRCULATION RESEARCH

Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

(2014) André J. Scheen   CLINICAL PHARMACOKINETICS

Effects of Sitagliptin on Glycemia, Incretin Hormones, and Antropyloroduodenal Motility in Response to Intraduodenal Glucose Infusion in Healthy Lean and Obese Humans and Patients With Type 2 Diabetes Treated With or Without Metformin

(2014) T. Wu et al.   DIABETES

Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors

(2014) B. Omar et al.   DIABETES

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal

(2014) A.J. Scheen et al.   DIABETES & METABOLISM

Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin

(2014) Itamar Raz et al.   DIABETES CARE

The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications

(2014) Angelo Avogaro et al.   DIABETES CARE

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

(2014) S. Bonner-Weir et al.   DIABETES OBESITY & METABOLISM

Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444)

(2014) J.H. Shon et al.   DIABETES OBESITY & METABOLISM

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

(2014) J. Farngren et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

(2014) G. Schernthaner et al.   DIABETES OBESITY & METABOLISM

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

(2014) P.-H. Groop et al.   DIABETES OBESITY & METABOLISM

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

(2014) Y. G. Kim et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study

(2014) R. E. Pratley et al.   DIABETES OBESITY & METABOLISM

A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes

(2014) M. Monami et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

(2014) T. M. E. Davis   DIABETES OBESITY & METABOLISM

The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits

(2014) R. E. J. Ryder   DIABETIC MEDICINE

Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial

(2014) S. Del Prato et al.   DIABETIC MEDICINE

Risk of pancreatitis in patients treated with incretin-based therapies

(2014) Juris J. Meier et al.   DIABETOLOGIA

Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus

(2014) Gillian M. Keating   DRUGS

Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

(2014) Greg L. Plosker   DRUGS

Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies

(2014) Elizabeth M. Round et al.   DRUGS & AGING

Heart failure and dipeptidyl peptidase-4 inhibitors

(2014) Henry Krum et al.   EUROPEAN JOURNAL OF HEART FAILURE

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat

(2014) Henrik H. Hansen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats

(2014) Robert B. Jones et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin

(2014) Thomas Forst et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase

(2014) Kohei Kaku et al.   EXPERT OPINION ON PHARMACOTHERAPY

Effects of Alogliptin in Chronic Kidney Disease Patients with Type 2 Diabetes

(2014) Yukinao Sakai et al.   INTERNAL MEDICINE

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

(2014) S. Brunton   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Which incretin-based therapy for type 2 diabetes?

(2014) André J Scheen   LANCET

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

(2014) Rury R Holman et al.   LANCET

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients

(2014) Giuseppe Derosa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients

(2014) Chihiro Imai et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials

(2014) M. Monami et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Comparison of GLP-1 Analogues versus Sitagliptin in the Management of Type 2 Diabetes: Systematic Review and Meta-Analysis of Head-to-Head Studies

(2014) Tiansheng Wang et al.   PLoS One

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

(2014) Chun-Jun Li et al.   Diabetology & Metabolic Syndrome

Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE)

(2014) Tomoya Mita et al.   Diabetology & Metabolic Syndrome

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials

(2014) K. Esposito et al.   BMJ Open

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

(2014) L. Li et al.   BMJ-British Medical Journal

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus

(2014) Toshitsugu Sugimoto   MEDICAL SCIENCE MONITOR

Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison

(2014) Paul Craddy et al.   Diabetes Therapy

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease

(2013) Jennifer B. Green et al.   AMERICAN HEART JOURNAL

Association Between Urinary Albumin Excretion and Low-density Lipoprotein Heterogeneity Following Treatment of Type 2 Diabetes Patients with the Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin: A Pilot Study

(2013) Shigemasa Tani et al.   American Journal of Cardiovascular Drugs

Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial

(2013) Juan C. Arjona Ferreira et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician?

(2013) André J. Scheen   ANNALES D ENDOCRINOLOGIE

Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

(2013) Sung-Ho Kim et al.   ARCHIVES OF PHARMACAL RESEARCH

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy

(2013) Anthony H. Barnett et al.   CLINICAL DRUG INVESTIGATION

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers

(2013) Christian Friedrich et al.   CLINICAL THERAPEUTICS

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade

(2013) B. A. Aulinger et al.   DIABETES

Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and "Isoglycemic" Intravenous Glucose

(2013) I. Vardarli et al.   DIABETES

Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls

(2013) D. J. Drucker   DIABETES

Metformin revisited: A critical review of the benefit–risk balance in at-risk patients with type 2 diabetes

(2013) A.J. Scheen et al.   DIABETES & METABOLISM

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial

(2013) Julio Rosenstock et al.   Diabetes & Vascular Disease Research

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

(2013) M. A. Nauck   DIABETES CARE

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes: A >=52-week randomized, double-blind study

(2013) H. Yki-Jarvinen et al.   DIABETES CARE

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?

(2013) P. C. Butler et al.   DIABETES CARE

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea

(2013) Guntram Schernthaner et al.   DIABETES CARE

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

(2013) R. G. Moses et al.   DIABETES OBESITY & METABOLISM

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents

(2013) A. Philis-Tsimikas et al.   DIABETES OBESITY & METABOLISM

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis

(2013) D. Wu et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

(2013) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

(2013) E. J. Rhee et al.   DIABETES OBESITY & METABOLISM

Effects of Add-On Treatment with Sitagliptin on Narrowing the Range of Glucose Fluctuations in Japanese Type 2 Diabetes Patients Receiving Insulin Therapy

(2013) Yutaka Mori et al.   Diabetes Technology & Therapeutics

A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study

(2013) Giuseppe Derosa et al.   Diabetes Technology & Therapeutics

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

(2013) Yifei Zhang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

(2013) B. Charbonnel et al.   DIABETOLOGIA

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

(2013) Y. G. Kim et al.   DIABETOLOGIA

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1^|^alpha; in type 2 diabetic patients with incipient nephropathy

(2013) Hiroki Fujita et al.   ENDOCRINE JOURNAL

Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease

(2013) German Ramirez et al.   Endocrine Practice

Efficacy and Safety of Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Insufficiently Controlled with Metformin and a Sulfonylurea

(2013) Sung-Chen Liu et al.   Endocrine Practice

Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation

(2013) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

(2013) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Efficacy and safety of Jentadueto® (linagliptin plus metformin)

(2013) André J Scheen   Expert Opinion On Drug Safety

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

(2013) Andre Scheen   Expert Opinion On Drug Safety

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

(2013) Yuki Fujii et al.   EXPERT OPINION ON PHARMACOTHERAPY

The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study

(2013) M. Al-Arouj et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry

(2013) A. K. Gitt et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Rationale, Design, and Baseline Characteristics of a Trial for the Prevention of Diabetic Atherosclerosis Using a DPP-4 Inhibitor: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)

(2013) Naoto Katakami et al.   Journal of Atherosclerosis and Thrombosis

Diabetic nephropathy: new approaches for improving glycemic control and reducing risk

(2013) Guntram Schernthaner et al.   JOURNAL OF NEPHROLOGY

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study

(2013) W David Strain et al.   LANCET

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

(2013) Anthony H Barnett et al.   LANCET

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

(2013) Young-Sun Lee et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Cardiovascular effects of gliptins

(2013) André J. Scheen   Nature Reviews Cardiology

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?

(2013) Marcel H. A. Muskiet et al.   Nature Reviews Nephrology

Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study

(2013) Yuya Nakamura et al.   NEPHRON CLINICAL PRACTICE

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes

(2013) André J. Scheen   POSTGRADUATE MEDICINE

Dipeptidyl peptidase-4: A key player in chronic liver disease

(2013) Minoru Itou   WORLD JOURNAL OF GASTROENTEROLOGY

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

(2013) Jorge Luiz Gross et al.   BMJ Open

Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients

(2013) Makoto Ayaori et al.   Journal of the American Heart Association

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

(2013) Chetan Karyekar et al.   Clinical Interventions in Aging

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

(2013) Anja Schweizer et al.   Diabetes Therapy

DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

(2012) Matteo Monami et al.   ADVANCES IN THERAPY

Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials

(2012) Matteo Monami et al.   ADVANCES IN THERAPY

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

(2012) Haesuk Park et al.   ANNALS OF PHARMACOTHERAPY

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study)

(2012) Masaya Sakamoto et al.   Cardiovascular Diabetology

Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

(2012) Larry K. Golightly et al.   CLINICAL PHARMACOKINETICS

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: Results from the randomized Optima study

(2012) B. Guerci et al.   DIABETES & METABOLISM

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

(2012) J. C. Arjona Ferreira et al.   DIABETES CARE

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment: A 1-year, randomized, double-blind, placebo-controlled study

(2012) J. B. McGill et al.   DIABETES CARE

Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis

(2012) W. Rathmann et al.   DIABETES OBESITY & METABOLISM

One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study

(2012) E. S. Hong et al.   DIABETES OBESITY & METABOLISM

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

(2012) W. Kothny et al.   DIABETES OBESITY & METABOLISM

A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti

(2012) R. Violante et al.   DIABETIC MEDICINE

Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors

(2012) A. J. Scheen   DIABETOLOGIA

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETOLOGIA

Cardiovascular Biology of the Incretin System

(2012) John R. Ussher et al.   ENDOCRINE REVIEWS

Saxagliptin overview: special focus on safety and adverse effects

(2012) Shamsa Ali et al.   Expert Opinion On Drug Safety

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes

(2012) Rosemarie Lajara   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes

(2012) R. A. DeFronzo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Vildagliptin Reduces Glucagon during Hyperglycemia and Sustains Glucagon Counterregulation during Hypoglycemia in Type 1 Diabetes

(2012) Johan Farngren et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes

(2012) S. Cornell   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

(2012) Vivian Fonseca et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Gliptin versus a sulphonylurea as add-on to metformin

(2012) André J Scheen et al.   LANCET

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease

(2012) Nasser Mikhail   POSTGRADUATE MEDICINE

Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

(2012) Masahiro Iwasaki et al.   Journal of Diabetes Investigation

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial

(2011) Nir Barzilai et al.   CURRENT MEDICAL RESEARCH AND OPINION

DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials

(2011) A.J. Scheen   DIABETES & METABOLISM

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

(2011) D. Russell-Jones et al.   DIABETES CARE

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study

(2011) E. Bosi et al.   DIABETES OBESITY & METABOLISM

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*

(2011) U. Graefe-Mody et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and HbA1c target of

(2011) K. Esposito et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

(2011) R. E. van Genugten et al.   DIABETES OBESITY & METABOLISM

Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment

(2011) M. Nowicki et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial

(2011) V. Lukashevich et al.   DIABETES OBESITY & METABOLISM

Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model

(2011) A. Gonçalves et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1

(2011) D. R. Owens et al.   DIABETIC MEDICINE

Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

(2011) Roberta Baetta et al.   DRUGS

The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

(2011) Midori Ito et al.   ENDOCRINE JOURNAL

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No

(2011) Sten Madsbad   European Journal of Internal Medicine

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: Yes

(2011) André J. Scheen   European Journal of Internal Medicine

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

(2011) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Metformin + saxagliptin for type 2 diabetes

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

A review of gliptins in 2011

(2011) André J Scheen   EXPERT OPINION ON PHARMACOTHERAPY

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

(2011) M. Nowicki et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Dipeptidylpeptitase-4 Inhibitors (Gliptins)

(2010) André J. Scheen   CLINICAL PHARMACOKINETICS

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

(2010) A. J. Scheen   DIABETES OBESITY & METABOLISM

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

(2010) André J. Scheen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

(2010) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

Addition of incretin therapy to metformin in type 2 diabetes

(2010) André J Scheen et al.   LANCET

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

(2008) J. C. N. Chan et al.   DIABETES OBESITY & METABOLISM

Assessing the Cardiovascular Safety of Diabetes Therapies

(2008) Allison B. Goldfine   NEW ENGLAND JOURNAL OF MEDICINE